Interpace Biosciences Q2 revenue falls despite growth in thyroid business - IDXG News | RalliesInterpace Biosciences Q2 revenue falls despite growth in thyroid business
I
IDXG• Outlook
- Company expects continued margin expansion through the remainder of 2026
- Interpace does not expect pancreatic cancer program to contribute revenue in 2026
Overview
- U.S. thyroid diagnostics firm's Q2 revenue fell 1% yr/yr, up 9% on a thyroid-only basis
- Company posted net income from continuing operations, reversing prior-year loss
- Gross margin expanded and adjusted EBITDA improved following shift to thyroid-only business
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Revenue | | $9.13 mln | |
| Q2 Net Income | | $158,000 | |
| Q2 Gross Profit | | $5.65 mln | |
| Q2 Net Income from Continuing Operations | | $266,000 | |
| Q2 Operating Expenses | | $5.33 mln | |
| Q2 Operating Income | | $321,000 | |
Result drivers
- Thyroid revenue growth - Co said 9% yr/yr increase in thyroid revenue and 6% rise in thyroid test volume supported results
- - Co attributed margin expansion to laboratory automation and AI-enabled productivity initiatives
Operational efficiency
Improved commercial execution - Co cited increased average revenue per test, improved days sales outstanding, and faster turnaround timesVGAS
•
